Compare TRGP & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRGP | ARGX |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.7B | 58.4B |
| IPO Year | 2010 | 2017 |
| Metric | TRGP | ARGX |
|---|---|---|
| Price | $261.18 | $878.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | $257.29 | ★ $1,008.56 |
| AVG Volume (30 Days) | ★ 1.1M | 270.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 47.91 | N/A |
| EPS | ★ 5.75 | N/A |
| Revenue | ★ $17,028,300,000.00 | N/A |
| Revenue This Year | $30.33 | $44.39 |
| Revenue Next Year | $6.55 | $20.84 |
| P/E Ratio | $44.67 | ★ $33.69 |
| Revenue Growth | ★ 3.95 | N/A |
| 52 Week Low | $144.14 | $636.10 |
| 52 Week High | $291.04 | $953.58 |
| Indicator | TRGP | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 50.36 |
| Support Level | $254.27 | $823.21 |
| Resistance Level | $261.95 | $881.89 |
| Average True Range (ATR) | 7.44 | 26.03 |
| MACD | -1.98 | -0.85 |
| Stochastic Oscillator | 10.29 | 43.00 |
Targa Resources Corp is a midstream firm that mainly operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset. It has two operating segments: Gathering and Processing, and, Logistics and Transportation (also referred to as the Downstream Business).
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.